Skip to Content
Merck
  • Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method.

Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method.

Scientific reports (2019-01-27)
Zongming Liu, Yanzhi Wang, Sheheryar Kabraji, Shaozhen Xie, Peichen Pan, Zhenning Liu, Jing Ni, Jean J Zhao
ABSTRACT

Breast cancer brain metastasis (BCBM) remains a major clinical problem. Approximately 10-16% of patients with breast cancer develop brain metastases (BCBM). However, no systemic therapy has gained regulatory approval for the specific treatment of BCBM and this remains an area of persistent, unmet medical need. Rapid, predictive and clinically-relevant animal models are critical to study the biology of brain metastases and to identify effective therapeutic approaches for patients with BCBM. Here, we describe a method for efficient establishment of orthotopic mouse models of patient-derived brain metastases via an improved intracarotid injection protocol that permits tumor cell growth in the unique brain microenvironment without compromising the blood-brain barrier (BBB). We demonstrate that our newly improved models of patient-derived brain metastases recapitulate the histologic, molecular, and genetic characteristics of their matched patient tumor specimens and thus represent a potentially powerful tool for pre-clinical and translational research.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5), liquid, clone 3B5, Calbiochem®
SKU
Pack Size
Availability
Price
Quantity